Neurocrine Biosciences (FRA:NB3) EBIT: €686 Mil (TTM As of Mar. 2026)


FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
95 GF Score
Price €141.20
GF Value €158.95
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences EBIT?

Neurocrine Biosciences FRA:NB3 +0.93% 95 EBIT is €686 Mil as of Mar. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 95/100 and a GF Value™ of €158.95 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Neurocrine Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €161 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €686 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neurocrine Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 was 20.14%. Neurocrine Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 89.66%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Neurocrine Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.94%.

Neurocrine Biosciences  (FRA:NB3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neurocrine Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=643.56 * ( 1 - 19.81% )/( (2418.186 + 2707.45)/ 2 )
=516.070764/2562.818
=20.14 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3955.301 - 272.853 - ( 1264.262 - max(0, 634.864 - 2154.386+1264.262))
=2418.186

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4243.863 - 397.9 - ( 1138.513 - max(0, 719.42 - 2107.226+1138.513))
=2707.45

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Neurocrine Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=643.56/( ( (465.601 + max(255.26, 0)) + (465.37 + max(249.293, 0)) )/ 2 )
=643.56/( ( 720.861 + 714.663 )/ 2 )
=643.56/717.762
=89.66 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(586.527 + 58.926 + 244.671) - (272.853 + 0 + 362.011)
=255.26

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(664.406 + 55.792 + 248.515) - (397.9 + 0 + 321.52)
=249.293

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Neurocrine Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=685.636/13874.332
=4.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences EBIT Related Terms

Neurocrine Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences EBIT Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.57 235.06 362.03 585.03 543.57

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.92 126.24 203.88 194.63 160.89

FRA:NB3 vs VTRS, ELAN, RGC: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's EV-to-EBIT falls into.


FRA:NB3
95GF Score
Neurocrine Biosciences Inc FRA:NB3
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €686 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €686 Mil mean?
Neurocrine Biosciences (FRA:NB3) has a EBIT of €686 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neurocrine Biosciences.
Is Neurocrine Biosciences' EBIT too high?
Neurocrine Biosciences' current EBIT is €686 Mil. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' EBIT compare to VTRS and ELAN?
Neurocrine Biosciences' EBIT of €686 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neurocrine Biosciences. Neurocrine Biosciences's current EBIT is €686 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €158.95, compared to a current price of €141.20 — trading 11.2% below its estimated fair value. The current EBIT is €686 Mil. Neurocrine Biosciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current EBIT is €686 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €141.20 is trading 11.2% below its estimated GF Value™ of €158.95. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for FRA:NB3:

  • EBIT: €686 Mil
  • GF Value™: €158.95 vs. price of €141.20 (11.2% below fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score

Get the complete analysis for FRA:NB3

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€141.20
Price
€158.95
GF Value